About Iantrek
Iantrek is a Healthcare company based in White Plains (United States) founded in 2019 by Sean Ianchulev. Developer of a minimally invasive eye surgery technology. Iantrek has raised $97.78 million across 4 funding rounds from investors including Visionary Ventures, Sectoral Asset Management and USVP. The company has 2 employees. Its chief executive, as recorded, is Sean Ianchulev. Iantrek offers products and services including CycloPen, AlloFlo, and C-Rex. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is IANTREK, INC. Its competitors include Sight Sciences, Alcon and Orbit Biomedical; 3 of its 3 listed competitors have raised funding.
Company details
Iantrek was founded in 2019 in White Plains, United States, within the medical devices sector focused on ophthalmology. A minimally invasive technology for eye surgery is developed, featuring an implantable biologic stent. This stent is surgically placed to boost aqueous outflow and decrease intraocular pressure, addressing conditions like glaucoma. Operations center on innovation in biologic implants for improved surgical outcomes in eye care.
- Headquarters White Plains, United States
- Employees 2
- Founders Sean Ianchulev
- SectorsHealthcare
- Website iantrekmed.com
- Social LinkedIn
- Legal Name Iantrek, Inc.
- Total Equity Funding$97.78M (USD)
in 4 rounds
- Latest Funding Round$30M (USD), Series C
Apr 2026
- InvestorsVisionary Ventures
& 5 more
- Employee Count2
Products & Services of Iantrek
Iantrek offers a comprehensive portfolio of products and services, including CycloPen, AlloFlo, and C-Rex.
System for controlled creation of cyclodialysis in glaucoma surgery.
Enhances outflow in eyes through precision scleral reinforcement.
Device for circumferential, excisional goniotomy procedures.
Funding Insights of Iantrek
Iantrek has successfully raised a total of $97.78M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $97.78M
- Total Rounds 4
- Last Round Series C — $30M
- First Round $23M
(Aug 2022)
- Investors Count 6
All 4 funding rounds of Iantrek with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $30M | Series C | – | – | |
| Aug 2025 | $42M | Series C | – | USVP | |
| Feb 2025 | $2.78M | Series B | – | – | – |
| Aug 2022 | $23M | Series B | – | Visionary Ventures, Sectoral | – |
6 investors in total: 6 institutional.
Investors in Iantrek
Iantrek has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Visionary Ventures, Sectoral Asset Management and USVP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital fund focused on life sciences investments. | 2019 | visionaryvc.com | Newport Beach, United States | |
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
VC firm that focuses on early stage investments in the US | usvp.com | Menlo Park, United States | ||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
| trinitycapital.com | ||||
Investment and partnership in health and life sciences companies are provided. | jsdradius.com | New York, USA |
Investor details for Iantrek
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Iantrek
5 people are tracked at Iantrek (4 in leadership, 1 in team); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Sean Ianchulev | Founder & CEO | Leadership |
Adam Szaronos | CEO | Leadership |
Mike H. | Chief Financial Officer | Leadership |
Sean Ianchulev M.D., Mph | Founder, Chairman Of The Board | Leadership |
Monty Montoya | Strategic Advisor | Team |
Complete people profiles for Iantrek
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Iantrek
3 dated milestones of Iantrek across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Iantrek is founded.
- Funding First funding round of $23.0M.
- Funding Latest funding round, Series C, of $30.0M.
Competitors of Iantrek
Iantrek has 3 listed competitors in our database, 3 of them funded. They include Sight Sciences, Alcon and Orbit Biomedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sightsciences.com | 2006 | Menlo Park, United States | $128.59M | 204 | Surgical systems for ophthalmological disease treatment are developed. | |
| alcon.com | 1945 | Fort Worth, United States | $171.61M | 25,315 | Developer of a wide range of eye care products | |
| orbitbiomedical.com | 2018 | Ambler, United States | $12M | Medical device for ophthalmic surgery is developed. |
Detailed competitors of Iantrek
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Iantrek
The website of Iantrek (iantrekmed.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 34.9% vs previous month
Top companies in Ophthalmology
3 companies that operate in the same segment as Iantrek (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iantrek
Complete news archive for Iantrek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Iantrek
Iantrek was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Iantrek is headquartered in White Plains, United States. It is registered at White Plains, New York, United States.
Sean Ianchulev is the CEO of Iantrek, as recorded in our data. They have also founded this company.
Iantrek is a funded company, having raised a total of $97.78M across 4 funding rounds to date. The company's 1st funding round was a Series B of $23M, raised on Aug 2022.
Iantrek has 2 employees.
Iantrek was founded in 2019 in White Plains, United States, within the medical devices sector focused on ophthalmology. A minimally invasive technology for eye surgery is developed, featuring an implantable biologic stent. This stent is surgically placed to boost aqueous outflow and decrease intraocular pressure, addressing conditions like glaucoma. Operations center on innovation in biologic implants for improved surgical outcomes in eye care.
Iantrek's top competitors include Alcon, Sight Sciences and Orbit Biomedical.
Iantrek offers CycloPen, AlloFlo, and C-Rex.
Iantrek has 6 investors. Key investors include Visionary Ventures, Sectoral Asset Management, USVP, JSD I Radius Special Situations, and Civilization Ventures.
Iantrek operates through Iantrek, Inc..